Cure SMA will host the world’s largest regular gathering on spinal muscular atrophy next month in Dallas, bringing together leading SMA researchers and clinicians, as well as families living with the disease. The 2018 Annual Cure SMA Conference is set for June 14-17 at the Hilton Anatole Hotel. Its first three days…
News
Two years after approving it, the 28-member European Union will begin enforcing its General Data Protection Regulation (GDPR) — a tough new law that aims to protect the EU’s 512 million citizens, including rare disease patients, from having their medical records misused, sold, or subject to extortion by hackers, third parties…
#CureSMA 2018 – Results of Phase 2 Test of Reldesemtiv in 70 SMA Patients Set for Release at Meeting
Results of an exploratory Phase 2 study evaluating the effectiveness of reldesemtiv (CK-2127107) for a first time in patients with spinal muscular atrophy (SMA) will be presented at the Cure SMA annual conference set for mid-June in Texas. Reldesemtiv is a next-generation fast skeletal muscle troponin activator (FSTA) being developed by Cytokinetics…
If 8-year-old Branden Lim had been born in Australia instead of Malaysia, his parents soon would have no problem obtaining Spinraza (nusinersen) to treat his spinal muscular atrophy (SMA). Australian Health Minister Greg Hunt recently announced that, effective June 1, his ministry would add the Biogen therapy to its Pharmaceutical…
The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner tonight in Washington, D.C. The 2018 Rare Impact Awards, to be held at the Andrew W. Mellon Auditorium, will be webcast via Facebook for those…
Patients with spinal muscular atrophy (SMA) types 2 and 3 are at risk of malnutrition, altered metabolic rates, and changes in body composition, a study reports. The study, “Comprehensive nutritional and metabolic assessment in patients with spinal muscular atrophy: Opportunity for an individualized approach,” appeared in…
The European Union isn’t doing enough to protect the 30 million or so people with rare diseases who live in its 28 member countries, officials meeting last week in Vienna said. More than 900 people from 58 nations attended the 9th European Conference on Rare Diseases & Orphan Drugs (ECRD), held…
Spinraza (nusinersen) improves motor skills in a broad range of children with spinal muscular atrophy (SMA) type 1, including those in more advanced disease stages, according to a study of patients in Germany taking part in an Expanded Access Program (EAP) for the treatment offered by its developer, Biogen. The study,…
A particular type of glial cell — non-neuronal cells of the nervous system — is important in communication between nerve cells and muscles, researchers report. The findings point to potential new targets for therapies that might prevent or lessen muscle fatigue in diseases like spinal muscular atrophy (SMA). The study, “…
Over the next 20 years, the number of Americans with spinal muscular atrophy (SMA) will rise from 10,000 to nearly 15,000 — and 8,000 of those living with SMA today will still be alive come 2038, predicts Kenneth Hobby, president of Cure SMA. The Chicago-based nonprofit has been working…
Recent Posts
- New study finds muscle stem cells are key to treating SMA
- The blessing and burden of relying on medical machines
- I’m not proud of it, but sometimes I miss being in the hospital
- Evrysdi shown to stabilize motor, lung function in adults with SMA: Study
- How the Winter Olympics can remind us of the power of imagination
